Continuous Glucose Monitoring Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

Continuous glucose monitoring (CGM) devices are the latest advancement in the diabetes monitoring devices market, in which a sensor is linked to the CGM device and is placed on the patient’s skin. The device measures glucose levels in the interstitial fluid at frequent intervals and provides data which is captured via a transmitter to the receiver. These newer devices are projected to show positive market growth in the forecast period, 2021-2029 owing to presence of factors such as increasing diabetic population, rise in technological development focusing on smart connectivity options thus providing remote monitoring by the physicians, rising demand for patient specific treatment approaches and continuous developing reimbursement scenario.

The current report provides analytical insights and complete understanding of the present and upcoming CGM devices market scenario. It includes market evaluation and forecast analysis for 2019-2029. Furthermore, a complete dissected-evaluation of the CGM devices market by segmenting the market based on components, application and diverse geographies has been incorporated. 

The global CGM devices market is bifurcated based on the components consisted in the device and application. The components are sub-segmented into sensors, transmitters & receivers and insulin pumps. CGM devices are predominantly used by diabetic patients and their use in healthy individuals has currently begun as a preventive care option. Application is thus sub-segmented into diabetic patients and healthy individuals.

Market estimation and forecast analysis for the aforementioned segments are provided for the time span from 2019-2029 and valued as US$ Mn. Additionally, the respective compound annual growth rates (CAGRs) for each of the segments has also been included for the time scale 2021-2029, by keeping its base year as 2020.

The CGM devices market is also evaluated based on various geographies viz., North America, Europe, Asia Pacific, Latin America & Middle East and Africa. These geographical regions are further sub segmented into United States, Canada, United Kingdom, Germany, China, Japan, Brazil, Mexico, Saudi Arabia, and South Africa. Market estimation and forecast analysis for the above mentioned geographies for the period 2019-2029 and respective growth rates for the duration 2021-2029 has been included in the current report.

The CGM devices market is dominated by several large and medium-scale companies rendering this market highly competitive. There lies a great opportunity for the newer key players with advanced and developed glucose monitoring devices with minimal invasion. The key industries in the CGM devices market are Abbott Laboratories, Echo Therapeutics, Inc., Dexcom, Inc., GlySens Incorporated, Medtronic plc, Senseonics Holdings, Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AgaMatrix, Inc., Glucovation, GlySure, Arkray USA, Inc., OrSense, Tandem Diabetes Care & Pinnacle Technology.

Based on applications, the global continuous glucose monitoring devices market is segmented as follows:

• Diabetic Patients
• Type 1 Diabetes
• Type 2 Diabetes
• Healthy Individuals

Continuous glucose monitoring (CGM) devices enable continuous monitoring of the blood glucose levels with provision of trend analysis thus rendering patient centric care. CGM devices are majorly utilized by diabetic populations to monitor the blood glucose levels, thus capturing a major market share in the overall diabetes care market. Healthy individuals have recently begun to use CGM devices to enhance lifestyle patterns and monitor sugar levels as preventive care, seizing a smaller market share. Type 1 diabetes is an autoimmune condition where external insulin is required to maintain the glucose level; whereas in case of Type 2 diabetes, the body is resistant to insulin, thus leading to high glucose levels. This condition is maintained by oral medications and in very rare cases require insulin therapy. The requirement of continuous monitoring of sugar levels in order to inject an appropriate dose of insulin amongst type 1 diabetes patients is the major factor for this segment to encapsulate a larger market share.

Based on components, the global continuous glucose monitoring devices market is segmented as follows:

• Sensors
• Transmitters & Receivers
• Insulin Pumps

Continuous glucose monitoring (CGM) devices enable continuous mapping of the blood glucose levels with provision of trend analysis thus facilitating patient centric care. For the purpose of this study, the global CGM devices market is segmented on the basis components utilized viz., sensors, transmitters and receivers, and insulin pumps. Among the aforementioned components, the transmitters & receivers predominate the CGM devices market in the base year 2020 owing to their higher costs. However, this trend is expected to change in the forecast period, wherein insulin pumps will have a higher contribution to the CGM devices market as the new technological developments have begun to fuse insulin pumps with CGM technology. Sensors are a constitutive part of the CGM system, where its sensitivity is essential to acquire accurate glucose levels in the interstitial fluids, and thus need to be replaced periodically to maintain accuracy. The contribution of the sensor segment is also projected to rise at a higher growth rate in the forecast period, owing to development of more sensitive technologies and rise in demand for CGM devices.

For the purpose of this study, the global continuous glucose monitoring devices market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

Among the considered geographies, North America lined up by Europe accounts for major share in the continuous glucose monitoring devices market due to rise in developed healthcare infrastructure with improving reimbursement policies, drive towards attaining a patient-centric healthcare approach and technological advancements in healthcare monitoring. The approval of Abbott’s FreeStyle Libre device, Dexcom’s G4 & G5 and Medtronic’s Enlite & Enlite 2 in North America and Europe will propel the growth of continuous glucose monitoring devices market in these regions. Rising prevalence of diabetes in emerging economies such as India, China, Latin America and Middle East & Africa is expected to fuel the global growth of CGM devices market. However, high pricing of CGM devices, discomfort observed among patients using CGM devices and insufficient existence of healthcare IT products and services may have an negative impact on the CGM devices market the developing economies.


This product will be delivered within 2 business days.